Telbivudine has activity against HIV-1

AIDS

Volumn 23, Issue 4, 2009, Pages 546-547

  Low, Emma ^a   Cox, Alison ^a   Atkins, Mark ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EFAVIRENZ; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MONOTHERAPY; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES;

EID: 62349140803     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283262f09     Document Type: Letter

References (5)

1. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
2. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: update recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410.
3. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718-723.
4. BARACLUDE (Product Labelling, Bristol-Meyers Squibb). March 2005.
5. McMahon M, Jilek B, Brennan T, Shen L, Zhou Y, Bhat S, et al. The antihepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, Abstract 136LB.